IGF2BP2 also inhibits the phosphotyrosine interaction domain containing 1 (PID1) expression through the DANCR/FOXO1 axis, leading to drug resistance in glioblastoma cells and promoting glioma progression [54]. This evidence concerns the gene IGF2BP2 and central nervous system cancer.